Glycated Albumin and Risk of Mortality in the US Adult Population
Autor: | Mary R Rooney, Natalie Daya, Olive Tang, John William McEvoy, Josef Coresh, Robert H Christenson, Elizabeth Selvin |
---|---|
Rok vydání: | 2022 |
Předmět: | |
Zdroj: | Clin Chem |
ISSN: | 1530-8561 0009-9147 |
DOI: | 10.1093/clinchem/hvab232 |
Popis: | Background Glycated albumin is of growing interest as an alternative biomarker of glycemia. However, the association of glycated albumin with long-term outcomes in the general population is uncharacterized. We evaluated the associations of glycated albumin and hemoglobin A1c (HbA1c) with mortality in US adults. Methods We conducted a prospective analysis of 12 915 participants in the National Health and Nutrition Examination Survey 1999–2004. We used Cox regression to characterize associations of glycated albumin and HbA1c with all-cause and cardiovascular mortality through 2014. We categorized glycated albumin based on percentiles corresponding to clinical cut-points for HbA1c. No diagnosed diabetes: Results Among US adults (mean age 46 years), the prevalence of diagnosed diabetes was 6.8%. Glycated albumin and HbA1c were highly correlated (r = 0.76). Over the median 16.8 years follow-up, there were 2818 deaths (652 cardiovascular). Adults with diagnosed diabetes and glycated albumin ≥84th percentile had the highest risk for all-cause mortality [hazard ratio (HR) 3.96, 95% CI 3.06–5.13] and cardiovascular mortality (HR 6.80, 95% CI 4.20–11.03). HbA1c had associations with all-cause and cardiovascular mortality that were similar to those for glycated albumin. Conclusions Among US adults, increased values of glycated albumin and HbA1c were associated with all-cause and cardiovascular mortality, particularly in persons with diagnosed diabetes. Glycated albumin may be a useful alternative test of glycemia. |
Databáze: | OpenAIRE |
Externí odkaz: |